Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | La Merie | Brief Report: Death Receptors TRAIL-R1-2

Brief Report: Death Receptors TRAIL-R1-2

The present Brief Report about molecules targeting the death receptors TRAIL-R1 and/or TRAIL-R2 (DR4 and/or DR5) provides a competitor analysis. R&D projects with antibodies, proteins and gene therapy targeting the death receptors for tumor necrosis factor alpha related apoptosis-inducing ligand (TRAIL) to treat solid and hematologic malignancies are discussed as of January 2008. Among the companies active in the field of death receptor targeting biologics are pioneers Human Genome Science and Genetech. A total of ten different molecules are in phase I and II clinical development in various clinical cancer indications.

The brief report with 22 pages describes the apoptosis pathways relevant for the target, the target itself and therapeutic strategies of targeting death receptors TRAIL-R1 and/or TRAIL-R2. The brief reports discusses the concerns and barriers in the development of death receptor targeting molecules and provides an assessment of the current clinical landscape. Each of the ten TRAI-R1 and/or TRAIL-R2 targeting molecules is presented in an executive summary with references. The Brief Report also includes a summary list of the target pipeline with other preclinical projects.

Index

* Definition of Apoptosis Pathway

* Target Description

* Therapeutic Strategies

* Concerns and Barriers in the Development

* Assessment

* Individual Project Profiles

* Target Pipeline Summary

The Target Pipeline Summary presents a list in a tabular format providing information on:

* Drug Codes,

* Target / Mechanism of Action,

* Class of Compound,

* Product Category,

* Company,

* Indication,

* R&D Stage and additional comments with a hyperlink leading to the source of information.

Publisher: La Merie

Product Line: Brief Report

Pages: 22

Release Date: January of 2008

Format: PDF

Product Code: LMBR0001

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions